Phase 3 Trial Launches to Assess EGFR Inhibitor for NSCLC Subset

🔗 Access full article via CureToday

Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer with the EGFR exon 20 insertion mutation.